Meinungen zu Vertex - 500 Beiträge pro Seite

[andre00]

Was meint Ihr, sollte man bei Vertex nochmal zukaufen oder lieber noch abwarten.
Und wo habt Ihr den Stoppkurs gesetzt.

mfG andre00

[DoktorKulka]

ich habe heute bei 95 verkauft und habe Kauflimit bei 78 gesetzt

mal sehen was geht, sollte allerdings der Wahlirrsinn weitergehen,setze ich Limit bei 65

gruss drkulka

[Timo57]

Hallo Doktorchen,

über Antje wettern, was ihr denn einfiele über vertex herzuziehen -
und dann selbst verkaufen und nicht wissen wie tief man wieder
einsteigen soll.

[scream]

Hallo Vertex-Anleger,
meiner Meinung nach sind Vertex und Protein Design Labs die beiden Topinvestments bei den Bios. Allein das Vertex ein Mittel gegen HIV in Phase 3 hat, rechtfertigt einen KAUF!
Charttechnisch sieht PDLI vielversprechend aus.
Also Kaufen was das Zeug hält.

[TheFrog]

Schaut doch mal rein: www.brokerstalk.de.vu

[FLOTSAM_AND_JETSAM_US]

VERTEX NEWS nach Börsenschluß

Tuesday December 12, 1:00 am Eastern Time
Press Release
SOURCE: Serono S.A.
Serono and Vertex Establish Collaboration to Develop and Market Caspase Inhibitors for the Treatment of Neurological and Inflammatory Diseases
GENEVA, Switzerland and CAMBRIDGE, Mass., Dec. 12 /PRNewswire/ -- Serono S.A. (NYSE: SRA; SWX: SEO) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - news) announced today that they have entered into a collaboration to discover, develop, and market caspase inhibitors. Caspase inhibitors are a class of compounds with the potential to treat serious neurological and inflammatory diseases. Under the terms of the agreement, Vertex could receive up to $95 million to support and expand Vertex`s drug discovery activities in the caspase protein family, including milestone payments as drug candidates move through development. The two companies expect to select a first drug development candidate in 2001.

``Serono will build on its commitment to the treatment of autoimmune and serious inflammatory diseases with a new generation of small molecule therapeutics that have the potential to treat life-threatening conditions through completely novel mechanisms of action,`` said Ernesto Bertarelli, CEO of Serono. ``This agreement gives us access to an established drug discovery program with near-term product development potential. The combination of Serono`s understanding of these diseases with Vertex`s leadership in the field of caspase inhibition gives us great confidence in the powerful potential of this collaboration.``

``Vertex`s chemogenomics approach has enabled us to move rapidly in the design and synthesis of multiple lead classes of compounds directed at caspase targets,`` said Joshua Boger, Ph.D., Chairman and CEO of Vertex. ``Vertex has established a strong intellectual property position in the discovery of caspase inhibitors. With the collaboration announced today, we will gain access to Serono`s substantial capabilities in molecular biology, pre-clinical pharmacology and development. This new partnership, combined with our collaboration with our Far East partner Taisho Pharmaceutical, allows Vertex to leverage our success and pursue additional caspase targets.``

Caspase inhibitors have the potential to prevent cell and tissue damage common to a range of diseases. Caspases comprise a family of 11 known human enzymes that play specific roles in apoptosis (programmed cell death) and inflammation. To increase the pace of drug discovery for structurally similar targets such as caspases, Vertex has pioneered the field of chemogenomics, which unites genomic information, structural biology and computational chemistry with other aspects of drug discovery.

Under the terms of the agreement announced today, Vertex will receive $5 million in payments for prior research, and could also receive up to $20 million in research funding over the next five years. Vertex could also receive an additional $70 million in milestone payments for the successful development and commercialization of more than one drug candidate. The two companies will share development costs. Vertex and Serono will establish a joint venture for the commercialization of products in North America, where they will share marketing rights and profits from the sale of caspase inhibitors. Serono will have exclusive rights to market caspase inhibitors in other territories, excluding Japan and certain other countries in the Far East, and will pay Vertex for the supply of drug substance. In November 1999, Vertex and Taisho Pharmaceutical established a collaboration to develop and market caspase inhibitors in Japan and certain Far East markets.

Vertex`s expertise in caspase inhibition

Vertex has conducted extensive research into the role of caspases in disease. As part of its drug discovery efforts to date in the caspase protein family, Vertex has determined the three-dimensional atomic structure of several caspases and caspase/inhibitor co-complexes. Vertex has also identified the physiological role of specific caspases using gene-targeting approaches. Using medicinal, computational and combinatorial chemistry, Vertex has generated lead classes of caspase inhibitors, and has patents issued or filed related to classes of caspase inhibitors and methods for discovering caspase inhibitors using Vertex`s proprietary technologies. The Company`s successful design and optimization of inhibitors of the inflammation target caspase-1 (ICE), has produced orally active compounds, including VX-740. Vertex`s partner, Aventis, is conducting Phase II trials with VX-740 in patients with rheumatoid arthritis. Vertex is currently conducting drug optimization studies to evaluate other inhibitors of caspases involved in apoptosis, and clinical testing of another Vertex-discovered caspase inhibitor could begin as early as 2002.

About Vertex

Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex has 12 drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary, information-intensive approach to drug design that integrates multiple technologies in biology, chemistry and biophysics, aimed at increasing the speed and success rate of drug discovery. Vertex`s first approved product is Agenerase(TM) (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with Glaxo Wellcome.

About Serono

Serono, headquartered in Geneva, Switzerland, is a global biotechnology leader. The company has four recombinant products on the market: Gonal-F®, Rebif®, Serostim®, and Saizen®. In addition to being the world leader in reproductive health, Serono has strong market positions in the therapeutic areas of neurology, metabolism and growth. The Company`s research programs are focused on growing these businesses and on establishing new therapeutic areas. Currently, there are seven molecules in development including six recombinant proteins.

In 1999, Serono achieved worldwide sales of US $1.054 billion and a net income of $183.7 million, making it the third largest biotech company based on revenues. The Company operates in 45 countries, and its products are sold in over 100 countries. Bearer shares of Serono S.A., the holding company, are traded on the SWX Swiss Exchange (SEO) and its American Depositary Shares are traded on the New York Stock Exchange (SRA).

Some of the statements in this press release are forward-looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements are based on the Company`s current expectations and assumptions, which may be affected by a number of factors, including those discussed below and more fully described in the Company`s prospectus filed with the U.S. Securities and Exchange Commission on July 26, 2000. These factors include any failure or delay in the Company`s ability to develop new products, any failure to receive anticipated regulatory approvals, any problems in commercializing current products as a result of competition or other factors, our ability to obtain reimbursement coverage for our products, and government regulations limiting our ability to sell our products. The Company has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.

SOURCE: Serono S.A.

[dr.omnex]

schön , schön , und was sagt uns das ?
mit meinem ausländisch ist es nicht so weit her (leider) .
kannste das nicht mal zusammenfassen und übersetzen !

[FLOTSAM_AND_JETSAM_US]

Vrtx arbeitet mit Serono zusammmen und hat dabei die Möglichkeit bis zu $95 Millionen vom Serenozu erhalten für R&D u. ähnliches
positive Meldung, mal sehen was der Markt heute macht>>>Wahlchaos

[dr.omnex]

Besten dank .Hört sich gut an .
Auf zu neuen Höhen (schwärm)!!!
Wenn nicht heute dann morgen .
Bernd Förtsch hat wieder mächtig die
Buschtrommel geschlagen !!! (hi hi)
Also ich bin sehr zuversichtlich
(habe ja auch schon rechzeitig zugeschlagen)

[Wuscher]

moin moin
VERTEX
DAS BESTE WAS ES AUF DEHM MARKT GIEBT !!!!!
mfg